The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.
Hair loss treatments discussed include dermarolling, minoxidil, finasteride, and RU58841. Some users find dermarolling sad, while others mention the complexity of biological systems and limited research funding for hair loss.
Microneedling can aid hair regrowth but poses risks like permanent hair loss if not done properly. Combining it with minoxidil, finasteride, and tretinoin, while ensuring proper sterilization and technique, is crucial for safety and effectiveness.
The conversation humorously discusses hair loss treatments, focusing on finasteride, dutasteride, minoxidil, and microneedling. Users share experiences and opinions on the effectiveness and side effects of these treatments.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
After one month of treatment for hair loss, which included Dutasteride, oral Minoxidil, PRP with Dutasteride mesotherapy, microneedling, supplements, and a shampoo with finasteride and minoxidil, the user observed thicker hair and signs of new hair growth with no bad side effects. They plan to provide another update at the three-month mark.
The user reports hair regrowth at the crown and thickening at the front after three months using 1mg finasteride, 0.5% minoxidil, biotin supplements, vitamin D, and argan oil shampoo and conditioner. They express a wish that hair growth could occur at the back of the head as well.
PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.